{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T17:39:28Z","timestamp":1793727568259,"version":"4.6.1"},"reference-count":174,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"funder":[{"name":"Viatris","award":["unconditional grant"],"award-info":[{"award-number":["unconditional grant"]}]}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Therapeutic Advances in Chronic Disease"],"published-print":{"date-parts":[[2025,10]]},"abstract":"<jats:p>Glatiramer acetate (GA) has been a pivotal therapy for relapsing multiple sclerosis (MS) due to its favorable safety profile. Long-term data spanning decades demonstrate its continued use in diverse patient populations. Adverse events include manageable localized injection site reactions, lipoatrophy or necrosis, and rare cases of liver injury. GA has minimal effects on immune function, and does not increase the risk of opportunistic infections, making it suitable for MS patients at risk for infections or reactivation of latent infections. GA\u2019s immunomodulatory properties may pose a lower infection risk than other disease-modifying treatments. Progressive multifocal leukoencephalopathy risk with GA is low, and screening for latent infection is unnecessary before treatment. Vaccination is important for preventing infections in MS patients. GA does not compromise vaccine efficacy and is compatible with both inactivated and live attenuated vaccines. Special populations that may benefit from the characteristics of GA include older adults and patients with comorbidities and\/or polypharmacy. MS patients often have comorbidities, necessitating careful management of potential drug interactions and side effects. Drug interactions with GA are not predicted, and clinical data suggest that the risk is low. GA is not contraindicated during pregnancy and exhibits a reassuring safety profile during breastfeeding, with no increased risk of adverse outcomes identified. Regulatory restrictions on GA use during breastfeeding have been removed. In summary, GA remains a safe and well-established therapy for MS patients, including those in special populations. Its favorable safety profile, compatibility with vaccination, and reassuring outcomes solidify its role in MS treatment.<\/jats:p>","DOI":"10.1177\/20406223251377965","type":"journal-article","created":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T01:47:29Z","timestamp":1760838449000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":3,"title":["A narrative review on the safety of glatiramer acetate in multiple sclerosis: focus on Europe"],"prefix":"10.1177","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8940-9317","authenticated-orcid":false,"given":"Refik","family":"Pul","sequence":"first","affiliation":[{"name":"Department of Neurology, Center for Translational Neuro- and Behavioral Sciences, University Medicine Essen, Hufelandstr. 55, Essen 45147, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8509-6563","authenticated-orcid":false,"given":"Jelena","family":"Skuljec","sequence":"additional","affiliation":[{"name":"Department of Neurology, Center for Translational Neuro- and Behavioral Sciences, University Medicine Essen, Essen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Santosh B.","family":"Shirol","sequence":"additional","affiliation":[{"name":"Global NCD Excellence, Viatris, Bangalore, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riyaz A.","family":"Saboor","sequence":"additional","affiliation":[{"name":"Global Product Safety and Risk Management, Viatris, Hyderabad, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Kleinschnitz","sequence":"additional","affiliation":[{"name":"Department of Neurology, Center for Translational Neuro- and Behavioral Sciences, University Medicine Essen, Essen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2025,10,18]]},"reference":[{"key":"e_1_3_4_2_2","doi-asserted-by":"publisher","DOI":"10.1002\/ana.410110314"},{"key":"e_1_3_4_3_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.45.7.1268"},{"key":"e_1_3_4_4_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.50.3.701"},{"key":"e_1_3_4_5_2","doi-asserted-by":"publisher","DOI":"10.1002\/ana.64"},{"key":"e_1_3_4_6_2","unstructured":"Teva Neuroscience. Copaxone prescribing information https:\/\/www.copaxone.com\/globalassets\/copaxone\/prescribing-information.pdf (2023 accessed 30 May 2023)."},{"key":"e_1_3_4_7_2","unstructured":"Teva. Copaxone\u2014summary of product characteristics. Electronic medicines compendium https:\/\/www.medicines.org.uk\/emc\/product\/183 (2022 accessed 11 October 2023)."},{"key":"e_1_3_4_8_2","doi-asserted-by":"publisher","DOI":"10.1002\/eji.1830010406"},{"key":"e_1_3_4_9_2","doi-asserted-by":"publisher","DOI":"10.2165\/11588120-000000000-00000"},{"key":"e_1_3_4_10_2","doi-asserted-by":"publisher","DOI":"10.1080\/17425247.2018.1418322"},{"key":"e_1_3_4_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejps.2019.03.011"},{"key":"e_1_3_4_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0165-5728(98)00166-0"},{"key":"e_1_3_4_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jneuroim.2009.06.011"},{"key":"e_1_3_4_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jneuroim.2010.04.022"},{"key":"e_1_3_4_15_2","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2377-12-95"},{"key":"e_1_3_4_16_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0051867"},{"key":"e_1_3_4_17_2","doi-asserted-by":"publisher","DOI":"10.1038\/nm1620"},{"key":"e_1_3_4_18_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40263-018-0567-8"},{"key":"e_1_3_4_19_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00018-009-8726-1"},{"key":"e_1_3_4_20_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1582-4934.2008.00640.x"},{"key":"e_1_3_4_21_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0062237"},{"key":"e_1_3_4_22_2","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2016.00437"},{"key":"e_1_3_4_23_2","doi-asserted-by":"publisher","DOI":"10.1111\/cei.12125"},{"key":"e_1_3_4_24_2","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1801235"},{"key":"e_1_3_4_25_2","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000000698"},{"key":"e_1_3_4_26_2","doi-asserted-by":"publisher","DOI":"10.4172\/2155-9899.1000258"},{"key":"e_1_3_4_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.metabol.2015.05.001"},{"key":"e_1_3_4_28_2","doi-asserted-by":"publisher","DOI":"10.1177\/1352458511420268"},{"key":"e_1_3_4_29_2","doi-asserted-by":"publisher","DOI":"10.1002\/eji.201040516"},{"key":"e_1_3_4_30_2","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.170.9.4483"},{"key":"e_1_3_4_31_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jneuroim.2003.11.014"},{"key":"e_1_3_4_32_2","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.172.11.7144"},{"key":"e_1_3_4_33_2","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awh163"},{"key":"e_1_3_4_34_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0812183106"},{"key":"e_1_3_4_35_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1009443107"},{"key":"e_1_3_4_36_2","doi-asserted-by":"publisher","DOI":"10.1191\/1352458502ms810oa"},{"key":"e_1_3_4_37_2","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000000179"},{"key":"e_1_3_4_38_2","doi-asserted-by":"publisher","DOI":"10.3390\/cells11091578"},{"key":"e_1_3_4_39_2","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.1859-05.2005"},{"key":"e_1_3_4_40_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2014.05.005"},{"key":"e_1_3_4_41_2","doi-asserted-by":"publisher","DOI":"10.1007\/s12035-007-8002-z"},{"key":"e_1_3_4_42_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0909607106"},{"key":"e_1_3_4_43_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11481-013-9436-x"},{"key":"e_1_3_4_44_2","doi-asserted-by":"publisher","DOI":"10.3390\/ijms222413419"},{"key":"e_1_3_4_45_2","unstructured":"Multiple Sclerosis International Federation. Atlas of MS\u20143rd Edition https:\/\/www.atlasofms.org\/chart\/united-kingdom\/disease-modifying-treatments\/barriers-to-accessing-dmts (2023 accessed 29 July 2025)."},{"key":"e_1_3_4_46_2","doi-asserted-by":"publisher","DOI":"10.1177\/1352458519845106"},{"key":"e_1_3_4_47_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11910-021-01118-x"},{"key":"e_1_3_4_48_2","doi-asserted-by":"publisher","DOI":"10.1177\/13596535211068617"},{"key":"e_1_3_4_49_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2023.104841"},{"key":"e_1_3_4_50_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0083757"},{"key":"e_1_3_4_51_2","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0140299","article-title":"Equivalent Gene Expression Profiles between Glatopa\u2122 and Copaxone\u00ae","volume":"10","author":"D\u2019Alessandro JS","year":"2015","unstructured":"D\u2019Alessandro JS, Duffner J, Pradines J, et al. Equivalent Gene Expression Profiles between Glatopa\u2122 and Copaxone\u00ae. PLoS One 2015; 10: e0140299.","journal-title":"PLoS One"},{"key":"e_1_3_4_52_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00216-015-9057-8"},{"key":"e_1_3_4_53_2","first-page":"714","article-title":"Demonstration of biological and immunological equivalence of a generic glatiramer acetate","volume":"16","author":"D\u2019 Alessandro J","year":"2017","unstructured":"D\u2019 Alessandro J, Garofalo K, Zhao G, et al. Demonstration of biological and immunological equivalence of a generic glatiramer acetate. CNS Neurol Disord Drug Targets 2017; 16: 714\u2013723.","journal-title":"CNS Neurol Disord Drug Targets"},{"key":"e_1_3_4_54_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ensci.2018.05.006"},{"key":"e_1_3_4_55_2","first-page":"449","article-title":"Comparison of Copaxone\u00ae and Synthon\u2019s therapeutically equivalent glatiramer acetate","volume":"74","author":"Arends RJ","year":"2019","unstructured":"Arends RJ, Wang D, Buurman M, et al. Comparison of Copaxone\u00ae and Synthon\u2019s therapeutically equivalent glatiramer acetate. Pharmazie 2019; 74: 449\u2013461.","journal-title":"Pharmazie"},{"key":"e_1_3_4_56_2","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2020.590527"},{"key":"e_1_3_4_57_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2015.10.007"},{"key":"e_1_3_4_58_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2015.2154"},{"key":"e_1_3_4_59_2","doi-asserted-by":"publisher","DOI":"10.1177\/1352458516688956"},{"key":"e_1_3_4_60_2","doi-asserted-by":"publisher","DOI":"10.1517\/14656560902802877"},{"key":"e_1_3_4_61_2","doi-asserted-by":"publisher","DOI":"10.1208\/s12248-013-9533-z"},{"key":"e_1_3_4_62_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jneuroim.2015.11.020"},{"key":"e_1_3_4_63_2","doi-asserted-by":"publisher","DOI":"10.1517\/14728222.2013.778829"},{"key":"e_1_3_4_64_2","doi-asserted-by":"publisher","DOI":"10.1038\/srep10191"},{"key":"e_1_3_4_65_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1222878110"},{"key":"e_1_3_4_66_2","unstructured":"Dutch Medicines Authority CBG. Public Assessment Report Scientific discussion Glatirameeracetaat Mylan 20 mg\/ml solution for injection (glatiramer acetate) NL\/H\/3213\/001\/DC https:\/\/db.cbg-meb.nl\/pars\/h115993.pdf (2016)."},{"key":"e_1_3_4_67_2","unstructured":"Viatris. Brabio 20 mg\/mL\u2014summary of product characteristics. Electronic Medicines Compendium https:\/\/www.medicines.org.uk\/emc\/product\/8536 (2022 accessed 11 October 2023)."},{"key":"e_1_3_4_68_2","unstructured":"Viatris. Brabio 40 mg\/mL\u2014summary of product characteristics. Electronic Medicines Compendium https:\/\/www.medicines.org.uk\/emc\/product\/9181\/smpc#gref (2022 accessed 11 October 2023)."},{"key":"e_1_3_4_69_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40120-017-0079-3"},{"key":"e_1_3_4_70_2","doi-asserted-by":"publisher","DOI":"10.1177\/0897190017725984"},{"key":"e_1_3_4_71_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejps.2019.03.029"},{"key":"e_1_3_4_72_2","first-page":"7151685","article-title":"Enduring clinical value of Copaxone\u00ae (glatiramer acetate) in multiple sclerosis after 20 years of use","volume":"2019","author":"Wynn DR.","year":"2019","unstructured":"Wynn DR. Enduring clinical value of Copaxone\u00ae (glatiramer acetate) in multiple sclerosis after 20 years of use. Mult Scler Int 2019; 2019: 7151685.","journal-title":"Mult Scler Int"},{"key":"e_1_3_4_73_2","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2022.844873"},{"key":"e_1_3_4_74_2","doi-asserted-by":"publisher","DOI":"10.1177\/1352458509358088"},{"key":"e_1_3_4_75_2","doi-asserted-by":"publisher","DOI":"10.1177\/13524585221094239"},{"key":"e_1_3_4_76_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.curtheres.2018.05.001"},{"key":"e_1_3_4_77_2","doi-asserted-by":"publisher","DOI":"10.1177\/1352458512438239"},{"key":"e_1_3_4_78_2","doi-asserted-by":"publisher","DOI":"10.2165\/00002018-200124130-00005"},{"key":"e_1_3_4_79_2","first-page":"247","article-title":"Long-term safety and tolerability of glatiramer acetate 20 mg\/ml in the treatment of relapsing forms of multiple sclerosis","volume":"16","author":"Ziemssen T","year":"2017","unstructured":"Ziemssen T, Ashtamker N, Rubinchick S, et al. Long-term safety and tolerability of glatiramer acetate 20 mg\/ml in the treatment of relapsing forms of multiple sclerosis. Expert Opin Drug Saf 2017; 16: 247\u2013255.","journal-title":"Expert Opin Drug Saf"},{"key":"e_1_3_4_80_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2015.06.005"},{"key":"e_1_3_4_81_2","unstructured":"European Medicines Agency. Direct Healthcare Professional Communication (DHPC) Glatiramer acetate: anaphylactic reactions may occur months up to years after treatment initiation https:\/\/www.ema.europa.eu\/en\/documents\/dhpc\/direct-healthcare-professional-communication-dhpc-glatiramer-acetate-anaphylactic-reactions-may-occur-months-years-after-treatment-initiation_en.pdf (2024)."},{"key":"e_1_3_4_82_2","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-022-01402-2"},{"key":"e_1_3_4_83_2","doi-asserted-by":"publisher","DOI":"10.1111\/cei.12226"},{"key":"e_1_3_4_84_2","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24010852"},{"key":"e_1_3_4_85_2","doi-asserted-by":"publisher","DOI":"10.1136\/bcr.09.2008.0913"},{"key":"e_1_3_4_86_2","article-title":"Drug-induced liver injury by glatiramer acetate used for treatment of multiple sclerosis: a case report","volume":"1","author":"Onmez A","year":"2013","unstructured":"Onmez A, Eminler AT, Ergen\u00e7 H, et al. Drug-induced liver injury by glatiramer acetate used for treatment of multiple sclerosis: a case report. J Investig Med High Impact Case Rep 2013; 1: 2324709613517493.","journal-title":"J Investig Med High Impact Case Rep"},{"key":"e_1_3_4_87_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-006-0441-3"},{"key":"e_1_3_4_88_2","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000450224.37865.80"},{"key":"e_1_3_4_89_2","doi-asserted-by":"publisher","DOI":"10.2174\/157488612802715690"},{"key":"e_1_3_4_90_2","doi-asserted-by":"publisher","DOI":"10.1007\/s13760-015-0506-0"},{"key":"e_1_3_4_91_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2014.08.001"},{"key":"e_1_3_4_92_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e3182a2cc4a"},{"key":"e_1_3_4_93_2","first-page":"280","article-title":"[Hepatitis induced by glatiramer acetate]","volume":"38","author":"Fern\u00e1ndez Fern\u00e1ndez N","year":"2015","unstructured":"Fern\u00e1ndez Fern\u00e1ndez N, Joao Matias D, Pisabarros Blanco C, et al. [Hepatitis induced by glatiramer acetate]. Gastroenterol Hepatol 2015; 38: 280\u2013281.","journal-title":"Gastroenterol Hepatol"},{"key":"e_1_3_4_94_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2013.09.008"},{"key":"e_1_3_4_95_2","doi-asserted-by":"publisher","DOI":"10.1177\/1756285617722352"},{"key":"e_1_3_4_96_2","first-page":"190","article-title":"[Autoimmune hepatitis in a patient with multiple sclerosis under treatment with glatiramer acetate]","volume":"55","author":"Arruti M","year":"2012","unstructured":"Arruti M, Castillo-Trivi\u00f1o T, de la Riva P, et al. [Autoimmune hepatitis in a patient with multiple sclerosis under treatment with glatiramer acetate]. Rev Neurol 2012; 55: 190\u2013192.","journal-title":"Rev Neurol"},{"key":"e_1_3_4_97_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2008.01982_9.x"},{"key":"e_1_3_4_98_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2020.101948"},{"key":"e_1_3_4_99_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10238-023-01128-8"},{"key":"e_1_3_4_100_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13317-020-00130-4"},{"key":"e_1_3_4_101_2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.28323"},{"key":"e_1_3_4_102_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40263-021-00842-9"},{"key":"e_1_3_4_103_2","unstructured":"US Food and Drug Administration. FDA adverse event reporting system https:\/\/www.fda.gov\/drugs\/questions-and-answers-fdas-adverse-event-reporting-system-faers\/fda-adverse-event-reporting-system-faers-latest-quarterly-data-files (2023 accessed 29 July 2025)."},{"key":"e_1_3_4_104_2","doi-asserted-by":"publisher","DOI":"10.1177\/1352458518799598"},{"key":"e_1_3_4_105_2","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2017-317493"},{"key":"e_1_3_4_106_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2019.3365"},{"key":"e_1_3_4_107_2","doi-asserted-by":"publisher","DOI":"10.1177\/13524585211069068"},{"key":"e_1_3_4_108_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2014.1472"},{"key":"e_1_3_4_109_2","doi-asserted-by":"publisher","DOI":"10.1038\/nrneurol.2016.21"},{"key":"e_1_3_4_110_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41582-020-00427-y"},{"key":"e_1_3_4_111_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2017.01.006"},{"key":"e_1_3_4_112_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2014.10.038"},{"key":"e_1_3_4_113_2","doi-asserted-by":"publisher","DOI":"10.1111\/ane.12835"},{"key":"e_1_3_4_114_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000001302"},{"key":"e_1_3_4_115_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000010380"},{"key":"e_1_3_4_116_2","doi-asserted-by":"publisher","DOI":"10.1136\/practneurol-2020-002527"},{"key":"e_1_3_4_117_2","article-title":"Factors associated with relapses in relapsing-remitting multiple sclerosis: a systematic review and meta-analysis","volume":"99","author":"Xie Y","year":"2020","unstructured":"Xie Y, Tian Z, Han F, et al. Factors associated with relapses in relapsing-remitting multiple sclerosis: a systematic review and meta-analysis. Medicine (Baltimore) 2020; 99: e20885.","journal-title":"Medicine (Baltimore)"},{"key":"e_1_3_4_118_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2021.103435"},{"key":"e_1_3_4_119_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000008157"},{"key":"e_1_3_4_120_2","doi-asserted-by":"publisher","DOI":"10.1177\/13524585231168043"},{"key":"e_1_3_4_121_2","doi-asserted-by":"publisher","DOI":"10.1111\/ene.13537"},{"key":"e_1_3_4_122_2","doi-asserted-by":"publisher","DOI":"10.1111\/cns.13034"},{"key":"e_1_3_4_123_2","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000000664"},{"key":"e_1_3_4_124_2","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.156978"},{"key":"e_1_3_4_125_2","doi-asserted-by":"publisher","DOI":"10.1177\/1352458520985118"},{"key":"e_1_3_4_126_2","doi-asserted-by":"publisher","DOI":"10.1097\/WCO.0000000000000701"},{"key":"e_1_3_4_127_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e3181cf6ec0"},{"key":"e_1_3_4_128_2","doi-asserted-by":"publisher","DOI":"10.1177\/1352458514561904"},{"key":"e_1_3_4_129_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000007035"},{"key":"e_1_3_4_130_2","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.2008.145805"},{"key":"e_1_3_4_131_2","doi-asserted-by":"publisher","DOI":"10.1111\/ene.15862"},{"key":"e_1_3_4_132_2","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2022-330887"},{"key":"e_1_3_4_133_2","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2021.799138"},{"key":"e_1_3_4_134_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000001187"},{"key":"e_1_3_4_135_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000004885"},{"key":"e_1_3_4_136_2","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2017.00577"},{"key":"e_1_3_4_137_2","doi-asserted-by":"publisher","DOI":"10.1177\/1352458519867314"},{"key":"e_1_3_4_138_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(23)00154-0"},{"key":"e_1_3_4_139_2","unstructured":"Coerver E Fung WH de Beukelaar J et al Discontinuation of first-line disease-modifying therapy in stable multiple sclerosis (DOT-MS): an early-terminated multicenter randomized controlled trial. Abstract Number: 1281\/O099. ECTRIMS-ACTRIMS. Milan https:\/\/s3.eu-central-1.amazonaws.com\/m-anage.com.storage.congrex\/abstracts_ectrims2023\/146784.pdf (2023 accessed 29 July 2025)."},{"key":"e_1_3_4_140_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2020.102507"},{"key":"e_1_3_4_141_2","doi-asserted-by":"publisher","DOI":"10.1177\/1352458514564491"},{"key":"e_1_3_4_142_2","doi-asserted-by":"publisher","DOI":"10.1177\/1352458514564490"},{"key":"e_1_3_4_143_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000002543"},{"key":"e_1_3_4_144_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2013.11.007"},{"key":"e_1_3_4_145_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.oftal.2016.11.018"},{"key":"e_1_3_4_146_2","doi-asserted-by":"publisher","DOI":"10.1080\/14740338.2020.1720646"},{"key":"e_1_3_4_147_2","doi-asserted-by":"publisher","DOI":"10.1177\/13524585221122207"},{"key":"e_1_3_4_148_2","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics14030592"},{"key":"e_1_3_4_149_2","doi-asserted-by":"publisher","DOI":"10.7224\/1537-2073.2014-076"},{"key":"e_1_3_4_150_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpsychores.2014.02.013"},{"key":"e_1_3_4_151_2","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.946351"},{"key":"e_1_3_4_152_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199807303390501"},{"key":"e_1_3_4_153_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000005065"},{"key":"e_1_3_4_154_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2020.102241"},{"key":"e_1_3_4_155_2","doi-asserted-by":"publisher","DOI":"10.1177\/17562864211051012"},{"key":"e_1_3_4_156_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40120-021-00297-6"},{"key":"e_1_3_4_157_2","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2022-330533"},{"key":"e_1_3_4_158_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(22)00426-4"},{"key":"e_1_3_4_159_2","doi-asserted-by":"publisher","DOI":"10.7224\/1537-2073.2016-079"},{"key":"e_1_3_4_160_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40264-022-01168-1"},{"key":"e_1_3_4_161_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-020-09913-1"},{"key":"e_1_3_4_162_2","doi-asserted-by":"publisher","DOI":"10.1177\/17562864211054956"},{"key":"e_1_3_4_163_2","doi-asserted-by":"publisher","DOI":"10.1111\/ene.16036"},{"key":"e_1_3_4_164_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2019.4173"},{"key":"e_1_3_4_165_2","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000000757"},{"key":"e_1_3_4_166_2","doi-asserted-by":"publisher","DOI":"10.1177\/13524585221083982"},{"key":"e_1_3_4_167_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2023.104771"},{"key":"e_1_3_4_168_2","doi-asserted-by":"publisher","DOI":"10.1159\/000504804"},{"key":"e_1_3_4_169_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000008907"},{"key":"e_1_3_4_170_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2020.101982"},{"key":"e_1_3_4_171_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2022.104245"},{"key":"e_1_3_4_172_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2020.102462"},{"key":"e_1_3_4_173_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2020.102184"},{"key":"e_1_3_4_174_2","doi-asserted-by":"publisher","DOI":"10.1186\/s42466-021-00143-y"},{"key":"e_1_3_4_175_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40263-021-00804-1"}],"container-title":["Therapeutic Advances in Chronic Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/20406223251377965","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/20406223251377965","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/20406223251377965","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T23:20:15Z","timestamp":1777591215000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/20406223251377965"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":174,"alternative-id":["10.1177\/20406223251377965"],"URL":"https:\/\/doi.org\/10.1177\/20406223251377965","relation":{},"ISSN":["2040-6223","2040-6231"],"issn-type":[{"value":"2040-6223","type":"print"},{"value":"2040-6231","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10]]},"article-number":"20406223251377965"}}